Venous Thromboembolism Therapy with Apixaban in Daily Care Patients: Results from the Dresden NOAC Registry.

TH Open · 2021 · PMC8096533 · PMID 33969261

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

We found a reassuringly low rate of unscheduled premature discontinuation (2.3% at 6 and 3.7% at 12 months) and a clear trend toward prolonged anticoagulant treatment with apixaban, since nearly 70% of patients were treated for longer than 6 months.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.